A cukorbetegség kezelése. dr. Hosszúfalusi Nóra Semmelweis Egyetem III. sz. Belgyógyászati Klinika

Drug induced diabetes mellitus ppt,

Intenzív konzervatív inzulin terápia napi többszöri inzulin injekció: a főétkezések előtt gyorshatású, éjszaka és esetleg reggel is elhúzódó hatású inzulin adása 2.

drug induced diabetes mellitus ppt

Folyamatos inzulinadás pumpa segítségével 3. Kivárás a sc. A betegség természete, szövődményei, az optimális beállítás előnyei.

Soronkívüli étkezés társasági vacsora, fogadás, stb. De: tökéletes bázisinzulin kell! McKeage K et al. Kramer W. Exp Clin Endocrinol Diabetes. New approaches to the treatment of diabetes. Bridgewater, NJ: Aventis Pharmaceuticals; Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and type 2 diabetes mellitus. Pharmacokinetics and dynamics of s.

drug induced diabetes mellitus ppt

Abstract Less hypoglycaemia with insulin glargine in intensive insulin therapy for mekkora a normál cukorszint 1 diabetes. Diabetes Care. Insulin glargine: a review of its therapeutic use as a long-lasting agent for the management of type 1 and type 2 diabetes mellitus. Treatment to target drug induced diabetes mellitus ppt insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes.

Successful control with less nocturnal hypoglycemia. Abstract P. Insulin glargine. The second profile shows, a more desirable profile with less fluctuations around the overall mean level References Russell-Jones D et al. Accepted for publication, Clinical Therapeutics 20 15 10 5 Russell-Jones D et ketoacidózis kezelés diabétesz 1-es típusú. References Russell-Jones D et al.

Clinical Therapeutics 29 Pancreas és Langerhans-sziget transzplantáció Kérdés: a DM vagy az immunszuppresszív kezelés veszélyei a nagyobbak?

Cardiovascularis kockázatcsökkentés a diabetológus szemével

Így a dominánsan inzulinrezisztens, túlsúlyos betegeknél az inzulinsensitizerek biguanidok és glitazonok alkalmazása javasolt elsődlegesen — testre szabott kezelés. Referenciák 1.

Diabetes Medications, Skills, \u0026 Calculations Lecture PPT

Henry RR. Jones TA et al. Diabet Obes Metab ; 5: — Viberti GC. Int J Clin Pract ; — Insulin-sensitizer should be preferred Insulin secretagog is preferred? Non-secretagog készítmények I. Alpha-glucosidase-hydroxylase gátlók Acarbose, Miglitol B. Insulin secretagog készítmények I. Sulfanylureák II.

Meglitinid származékok pl. D-Phenylalanin származékok pl.

Az előadások a következő témára: "A cukorbetegség kezelése"— Előadás másolata:

DPP-4 dipeptidyl-peptidase-4 gátlók un. Rosiglitazon és pioglitazon nem [alig] hepatotoxikus testsúly növekedés, folyadék retenció! Rosiglitazon mellett EKG sz.

drug induced diabetes mellitus ppt

Hosszútávú hatékonyság főleg kombinációban jó Kombinálhatók: sulfanylurea készítményekkel és az újabb secretagog gyógyszerekkel is kombinálhatók elvben metforminnal is, de: GI mellékhatások hasonlóak! Glibenclamide kifejezetten elnyújtott hatás hypoglyk.

Six young healthy subjects were given a 25, 50, or g oral glucose load or isoglycaemic intravenous glucose infusions. The g data is shown above. C-peptide may be a better measure of insulin secretion than plasma insulin, because C-peptide levels are not affected by hepatic insulin extraction. This difference in C-peptide levels in response to oral vs intravenous glucose suggests that other factors incretinsand not merely the direct actions of plasma glucose, affect the insulin secretory response.

drug induced diabetes mellitus ppt

Incretin Effect 5. Nauck MA, et al.

A cukorbetegség kezelése. dr. Hosszúfalusi Nóra Semmelweis Egyetem III. sz. Belgyógyászati Klinika

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. It demonstrated that after a meal, Glucose began to rise.

Baseline level was 83 ± 1. Drug induced diabetes mellitus ppt returned to baseline levels by minutes. Insulin followed a similar pattern. Glucagon, however, dropped to a low by 90 minutes, then increased to a level above that of the baseline level. Adapted from Woerle HJ et al. Am J Physiol Endocrinol Metab. Reference: 1. Pathways for glucose disposal after meal ingestion in humans.

These abnormalities contribute markedly to hyperglycemia both at the level of body tissues where insulin is not sufficient to drive glucose uptake and at the level of the liver where increased glucagon and decreased insulin cause the liver to inappropriately release glucose into the blood, thereby causing fasting hyperglycemia or increasing postprandial hyperglycemia. Adapted from Müller WA et al. N Engl J Med.

References: 1. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycemia. J Clin Invest. Adapted from Lebovitz HE et al.

Their blood glucose levels were monitored throughout the infusion period. However, GLP-1 infusion induced a significant reduction of both overnight from 7.

Islets were maintained in culture for five days in the presence or absence of GLP At day 1, islets maintained their physiologic spherical shape panel A. By day 3, many islets showed a progressive loss of structure, losing the acellular membrane that surrounds them panel C. At day 5, the three-dimensional structure of many cell aggregates had deteriorated to a two-dimensional structure typical of a cell monolayer panel E.

In contrast, islets treated with GLP-1 retained their three-dimensional organization for a longer period of time panels B, D, and F. Reference 1. Glucagon-like peptide inhibits cell apoptosis and improves glucose responsiveness drug induced diabetes mellitus ppt freshly isolated human islets. Endocrinology ;— Beta-cell mass and pancreatic functions were assessed on Day 7 and at 2 months.

Results from the GLP-1 injection are shown here. The GK rat is a genetic model of type 2 diabetes in which basal hyperglycaemia is first detectable three weeks after birth.